Is VRUS a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

98 people get VRUS articles and Market Currents by email alert.

Get email alerts on VRUS »

HEADLINES:

Idenix Pharmaceuticals: A Hepatitis C Play Revisited
EXPstocktrader • Tue, Jun 12, 2012
John Paulson's Big 2012 Bets
Alpha Stratus • Wed, May 30, 2012
Joe DiMenna's Top Stock Picks
Insider Monkey • Sat, Mar 17, 2012
On Fourth-Quarter 13Fs
David Merkel • Thu, Mar 1, 2012 • 1 Comment
Hepatitis C Remains A Hot Play
The Burrill Report • Mon, Feb 27, 2012
John Paulson Continues Massive 'De-Risking' In Q4
Alpha Stratus • Thu, Feb 16, 2012 • 2 Comments
Biopharma Report Card: 2-Week Checkup
Scott Matusow • Mon, Feb 6, 2012 • 25 Comments
11 Large-Cap, Low Debt Stocks For Defensive Investors
Insider Monkey • Mon, Jan 30, 2012
Johnson & Johnson: The Turnaround Is Starting And I Am A Buyer
Smith On Stocks • Mon, Jan 30, 2012 • 16 Comments
Top Healthcare Stocks With The Highest Upside Potential
Insider Monkey • Wed, Jan 25, 2012
Merger Arbitrage Mondays: Jan. 23, 2012
Asif Suria • Mon, Jan 23, 2012 • 5 Comments
Achillion's Hepatitis C Pipeline Is A Longshot
Adam Gefvert • Thu, Jan 19, 2012 • 27 Comments
2 Major Biotech Trends In 2012
Marc Lichtenfeld • Thu, Jan 19, 2012
A Bio-Pharma Buy And Sell List: Part 1
Scott Matusow • Wed, Jan 18, 2012 • 11 Comments
5 Risky Biotech Stocks To Avoid, 2 To Consider
Dividend Kings • Wed, Jan 18, 2012 • 9 Comments
Biogen's Big Multiple Sclerosis Bet Is About To Be Rewarded ... Again
Todd Campbell • Tue, Jan 17, 2012 • 3 Comments
Biotech Stocks On A Tear: I Like Celgene
Bill Gunderson • Fri, Jan 13, 2012 • 8 Comments
Analyzing 5 Biotech Stocks And Their Takeover Potential
Helix Investment Research • Fri, Jan 13, 2012 • 8 Comments
Vertex: Resolutions For The New Year Should Be Shareholder Friendly
Todd Campbell • Wed, Jan 11, 2012 • 1 Comment
Pharmasset, Inhibitex Receive Takeover Bids - Is Achillion Next?
Smith On Stocks • Mon, Jan 9, 2012 • 5 Comments

To learn more about Seeking Alpha Pro, click here.

Pharmasset: M&A Presents Interesting Options Plays
Nino Armienti • Wed, Jan 4, 2012 • 3 Comments
Pharmasset Is A Good Acquisition Arbitrage Play
Adam Gefvert • Wed, Dec 7, 2011 • 5 Comments
Pharmasset: The Real Numbers Behind the Hype
Robert Weinstein • Fri, Mar 11, 2011 • 15 Comments
Pharmasset Rides High on Compound Development for HCV Drugs
Jason Chew • Thu, Nov 4, 2010 • 8 Comments
Pharmasset's Hepatitis C Drug Has A Promising Future
A. Reza Saadat • Fri, Oct 5, 2007

Idenix Pharmaceuticals: A Hepatitis C Play Revisited
EXPstocktrader • Tue, Jun 12, 2012
John Paulson's Big 2012 Bets
Alpha Stratus • Wed, May 30, 2012
Joe DiMenna's Top Stock Picks
Insider Monkey • Sat, Mar 17, 2012
On Fourth-Quarter 13Fs
David Merkel • Thu, Mar 1, 2012 • 1 Comment
Hepatitis C Remains A Hot Play
The Burrill Report • Mon, Feb 27, 2012
John Paulson Continues Massive 'De-Risking' In Q4
Alpha Stratus • Thu, Feb 16, 2012 • 2 Comments
Biopharma Report Card: 2-Week Checkup
Scott Matusow • Mon, Feb 6, 2012 • 25 Comments
11 Large-Cap, Low Debt Stocks For Defensive Investors
Insider Monkey • Mon, Jan 30, 2012
Johnson & Johnson: The Turnaround Is Starting And I Am A Buyer
Smith On Stocks • Mon, Jan 30, 2012 • 16 Comments
Top Healthcare Stocks With The Highest Upside Potential
Insider Monkey • Wed, Jan 25, 2012
Merger Arbitrage Mondays: Jan. 23, 2012
Asif Suria • Mon, Jan 23, 2012 • 5 Comments
Achillion's Hepatitis C Pipeline Is A Longshot
Adam Gefvert • Thu, Jan 19, 2012 • 27 Comments
2 Major Biotech Trends In 2012
Marc Lichtenfeld • Thu, Jan 19, 2012
A Bio-Pharma Buy And Sell List: Part 1
Scott Matusow • Wed, Jan 18, 2012 • 11 Comments
5 Risky Biotech Stocks To Avoid, 2 To Consider
Dividend Kings • Wed, Jan 18, 2012 • 9 Comments
Biogen's Big Multiple Sclerosis Bet Is About To Be Rewarded ... Again
Todd Campbell • Tue, Jan 17, 2012 • 3 Comments
Biotech Stocks On A Tear: I Like Celgene
Bill Gunderson • Fri, Jan 13, 2012 • 8 Comments
Analyzing 5 Biotech Stocks And Their Takeover Potential
Helix Investment Research • Fri, Jan 13, 2012 • 8 Comments
Vertex: Resolutions For The New Year Should Be Shareholder Friendly
Todd Campbell • Wed, Jan 11, 2012 • 1 Comment
Pharmasset, Inhibitex Receive Takeover Bids - Is Achillion Next?
Smith On Stocks • Mon, Jan 9, 2012 • 5 Comments

Pharmasset's CEO Hosts Shareholder Analyst Call - Conference Call Transcript
Thu, Nov 3, 2011

Pharmasset Announces Intent to Amend QUANTUM Trial

PR Newswire (Dec 16, 2011)
Cramer: How to Track Down Speculative Winners

at CNBC.com (Nov 22, 2011)
Movers & Shakers: Monday’s biggest gaining and declining stocks

at MarketWatch.com (Nov 21, 2011)
Four-fifths of investors think Gilead overpaid: survey

at MarketWatch.com (Nov 21, 2011)
Indications: Wall Street set for drop on U.S., Europe worries

at MarketWatch.com (Nov 21, 2011)
Before the Bell: U.S. deficit-cut panel, Moody’s warnings in focus

at MarketWatch.com (Nov 21, 2011)
Stocks to Watch: Stocks to Watch Tuesday: Netflix, Insmed

at MarketWatch.com (Oct 10, 2011)
Movers & Shakers: Tuesday’s biggest gaining & declining stocks

at MarketWatch.com (Sep 6, 2011)
Biotech Stocks: Drug stocks flat, but Pharmasset climbs

at MarketWatch.com (Jul 6, 2011)
Cramer's Lesson In Good Investing

at CNBC.com (Jun 9, 2011)
Movers & Shakers: Wednesday’s biggest gaining and declining stocks

at MarketWatch.com (Jun 8, 2011)
Biotech Stocks: Impax leads drug stocks lower

at MarketWatch.com (Jun 8, 2011)
Biotech Stocks: Drug stocks mixed; Valeant, Nabi gain

at MarketWatch.com (May 24, 2011)
Earnings Watch: Updates, advisories and surprises

at MarketWatch.com (Apr 25, 2011)
Movers & Shakers: Monday’s biggest gaining and declining stocks

at MarketWatch.com (Apr 25, 2011)
Biotech Stocks: Alexion leads retreat in biotech stocks

at MarketWatch.com (Apr 25, 2011)
Cramer's Most Important Lesson In Speculating

at CNBC.com (Apr 8, 2011)
Lightning Round: VMware, Yum! Brands, Annaly Capital Management and More

at CNBC.com (Apr 5, 2011)
Movers & Shakers: Thursday’s biggest gaining and declining stocks

at MarketWatch.com (Mar 31, 2011)
Biotech Stocks: Pharmasset leads gains in drug stocks

at MarketWatch.com (Mar 31, 2011)

VRUS vs. ETF Alternatives

Company Description

Currently, there's no company description for VRUS.

Sector: Healthcare

Industry: Drug Manufacturers - Other

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Friday, January 27, 2012, 8:56 AM Idenix Pharmaceuticals (IDIX) -9.6% after Stifel Nicolaus downgrades shares to Sell from Hold at Stifel Nicolaus, which believes the "significant difference" in potency existing between IDIX's hepatitis C drug and those made by Pharmasset (VRUS) and Inhibitex (INHX) has important implications on how remaining "potential consolidators" strategically view the companies. Comment! [Healthcare, On the Move]
Friday, December 30, 2011, 8:05 PM Top five Dow gainers of 2011: MCD +31%, IBM +27%, PFE +24%, HD +20%, KFT +20%. Top S&P gainers: COG +103%, EP +92%, ISRG +81%, MA +69%, BIIB +65%. Top Nasdaq gainers: VRUS +469%, EGAN +412%, SIMO +392%, INHX +308%, TSTF +276%. 1 Comment
Friday, December 16, 2011, 10:38 AM JPMorgan weighs in on the Gilead Sciences (GILD -1.1%)-Pharmasset (VRUS -2.3%) merger after Pharmasset amended its phase 2b quantum trails this morning, rocking the boat of hepatitis C-related companies. "This announcement does not trigger a 'key product event' of the merger agreement. As such, we anticipate the deal will close on schedule." Comment! [On the Move, Healthcare]
Friday, December 16, 2011, 9:59 AM Following news that Pharmasset (VRUS -3.4%) will discontinue Phase 2b trials of its hepatitis drug, other hepatitis-related companies are seeing dramatic share movement. Rallying: VRTX +3.9%, ACHN +1.4%. Declining: INHX -27%, IDIX -13.3%. Comment! [On the Move, Healthcare]
Friday, December 16, 2011, 8:35 AM Pharmasset (VRUS) drops 3.6% after announcing it will "discontinue all treatment" in ongoing Phase 2b trials that involves use of its PSI-938 hepatitis drug. The company says it "detected laboratory abnormalities associated with liver function" in patients using PSI-938. Comment! [Healthcare, On the Move]
Wednesday, December 7, 2011, 5:27 PM While Pharmasset (VRUS) shareholders stand to reap a windfall from Gilead Sciences’ (GILD) $11B takeover offer, its top execs are also in line for fat paydays. According to SEC filings reviewed by Footnoted, VRUS CEO P. Schaefer Price could pocket $255M once the deal closes, and other top brass also would grow much richer. Comment! [M&A, Healthcare]
Thursday, December 1, 2011, 2:36 PM Benzinga notes shares of Pharmasset (VRUS -1.4%) are trading a little funky this week considering the strong market rally and its blockbuster sale to Gilead Sciences (GILD -0.4%). Despite a pickup in chatter that the deal is in jeopardy - a check with analysts covering GILD say the merger is still a "go." Comment! [M&A, Healthcare]
Monday, November 28, 2011, 3:06 PM Gilead Sciences (GILD +1.4%) keeps the positive momentum churning after announcing it landed EU approval for its Eviplera treatment for HIV-1 infection - clearing the way for the commercial development of the drug in all 27 member countries. Shares of GILD now stand just a hair below where they traded just prior to the announcement of its blockbuster purchase of Pharmasset (VRUS +0.1%). Comment! [Healthcare]
Monday, November 28, 2011, 7:30 AM Goldman Sachs adds Gilead Sciences (GILD) to its Conviction Buy list, calling its acquisition strategy "transformational." Analysts with the firm set a $46 price target on shares - hailing the mega-acquisition of Pharmasset (VRUS) as a move that changes the stock to a value story from a growth story. Comment! [Healthcare, Quick Ideas]
Tuesday, November 22, 2011, 11:33 AM Gilead Sciences (GILD +5.9%) trades higher after investors further digest the ramifications of its mega-acquisition of Pharmasset (VRUS -0.1%) that sent shares skittishly lower yesterday. Citi took a look at the deal, deciding to upgrade GILD to Buy from Neutral, seeing a potential for the now-bigger company to dominate the Hepatitis C treatment market. Comment! [On the Move, Healthcare]
Monday, November 21, 2011, 3:41 PM CNBC reports (video) an unusually high volume of call options in Pharmasset (VRUS +84.7%) were purchased just a few days before the buyout of the company by Gilead Sciences (GILD -9.7%). Analysts say the activity may get more than a passing glance look from regulators. 4 Comments [On the Move, Healthcare]
Monday, November 21, 2011, 9:00 AM Premarket gainers: GEDU +96%. VRUS +86%. INHX +30%. CLDX +8%. CTIC +6%. CLWR +6%. DNDN +6%. CBE +5%.
Losers: GERN -7%. KYG -6%. GILD -6%. RIO -5%. FRO -5%. RDN -4%. LNKD -4%. MT -4%. AIXG -3%. INVN -3%. GMCR -3%. CIM -3%. RIMM -3%. ANR -3%. BCS -3%. JEF -3%. AKS -3%. MPEL -3%. MU -3%. RMBS -3%. BHP -3%. DB -3%. TM -3%. NOK -3%. IHG -3%. BIDU -3%. PCX -3%. VALE -3%. Comment! [On the Move]
Monday, November 21, 2011, 8:00 AM Shares of Hepatitis C treatment providers Inhibitex (INHX) and Vertex Pharmaceuticals (VRTX) show upward momentum following the news of Gilead's (GILD) blockbuster deal to buy Pharmasset (VRUS). Premarket: INHX +31%, VRTX +2%. Comment! [On the Move]
Monday, November 21, 2011, 7:17 AM Gilead Sciences (GILD) announces a deal to purchase Pharmasset (VRUS) for $11B in a deal that is expected to close in Q1 and become accretive to Gilead's earnings starting in 2015. The $137/share offer price agreed upon by the firms marks an 89% premium to the closing price of Pharmasset on Friday. 2 Comments [M&A, Healthcare]
Tuesday, November 15, 2011, 12:05 PM Wedbush takes a shine to Idenix Pharmaceuticals (IDIX +3.5%), ringing up an upgrade to Outperform from Neutral to go along with a $5 price target hike to $11. Analysts with the firm tie the new rating to the "heightened premium" they see big-pharma placing on the nucleotide class of drugs following positive data released on Pharmasset’s (VRUS +2.3%) PSI-7977 treatment. Comment! [Healthcare]
Monday, November 7, 2011, 11:51 AM Pharma Wars: Shares of Vertex Pharmaceuticals (VRTX -7.9%) and Achillion Pharmaceuticals (ACHN -5.4%) move lower after separate announcements from Pharmasset (VRUS +2.2) and Inhibitex (INHX +14.3%) on drug treatments look set to affect sales for the firms of their competing products. Trading volume on all four companies is high. Comment! [On the Move, Healthcare]

Michael Kudrna
EXPstocktrader: The Hepatitis C Gold Rush $IDIX $ILMN $INHX $MRK $VRUS $$ #biotech #KSMT http://bit.ly/zInIwE
2/15/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Jacob Wolinsky
Pre-Market Morning News: Raymond James Buys Morgan Keegan http://bit.ly/xqlR4f $GOOG $ERO $USCR $CMC $RBS $GILD $VRUS $RF $GS
1/12/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Tony Kau
Today's Top Trend Exhaustion Sells: $VRUS $GILD $CP $VAL $CMC $DOW $RY $PTR $T $GOOG http://bit.ly/xpzV7Z
1/5/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Todd Campbell
$VRUS stumble may drive investors to revisit $VRTX http://bit.ly/tmd7fG
12/16/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Kinetic Investments
$VRTX -Will Vertex be punished or helped by the recent huge acquisition of $VRUS by $GILD ? VRTX trading near 52 week lows... VRTX GILD VRUS
11/22/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Bryant
Impressive. "Gilead to pay $11B to buy Pharmasset." Buy Gilead Sciences (GILD) on Pharmasset (VRUS) integration. http://bit.ly/vcSVoq
11/21/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Asif Suria
Gilead to buy Pharmasset for $11 billion for $11 billion $GILD $VRUS http://reut.rs/voSBc3
11/21/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

John Rayhall
Sell INHX on the VRUS pop?
11/21/11
Reply (9)

• !Report Abuse
View all 9 replies
emburns: I thought about buying VRUS last week...
11/21/11
• !Report Abuse
John Rayhall: Impossible to know what's going to happen in the M&A space
11/21/11
• !Report Abuse
Add a reply...

140 characters

Jacob Wolinsky
Monday Morning Pre-Market News http://bit.ly/rNzu1N $SPY $ERO $EWG $GS $UBS $AMZN $VRUS $GILD $TRH $Y $C
11/21/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

talbano
for a crappy morn - i a st least have 100 shares of VRUS
11/21/11
Reply (5)

• !Report Abuse
View all 5 replies
talbano: it got sold ah on Friday 20k shares, i almost dumped it seeing that ...glad i didn't
11/21/11
• !Report Abuse
Ocean Man: Never trust AH moves.
11/21/11
• !Report Abuse
Add a reply...

140 characters

LATEST REPLIES

John Rayhall
Sell INHX on the VRUS pop?
11/21/11
Reply (9)

• !Report Abuse
View all 9 replies
emburns: I thought about buying VRUS last week...
11/21/11
• !Report Abuse
John Rayhall: Impossible to know what's going to happen in the M&A space
11/21/11
• !Report Abuse
Add a reply...

140 characters

talbano
for a crappy morn - i a st least have 100 shares of VRUS
11/21/11
Reply (5)

• !Report Abuse
View all 5 replies
talbano: it got sold ah on Friday 20k shares, i almost dumped it seeing that ...glad i didn't
11/21/11
• !Report Abuse
Ocean Man: Never trust AH moves.
11/21/11
• !Report Abuse
Add a reply...

140 characters

Michael Bryant
I don't think I want to bet big on Inhibitex (INHX), but Pharmasset (VRUS) is a winner. http://bit.ly/vl8iO5
11/7/11
Reply (2)

• !Report Abuse
View all 2 replies
talbano: someone is going to have to step up and buy VRUS
11/7/11
• !Report Abuse
Michael Bryant: I'm guessing Merck (MRK) or Pfizer (PFE) will.
11/8/11
• !Report Abuse
Add a reply...

140 characters

Justin M. Hall
8/6/11 12A ET: (VRUS, ALXN, BIIB, ILMN, PRGO) BIOTECH CORRECTION Called in June 2011 => Were You Paying Attention? http://seekingalpha.com/p/4bsg
8/6/11
Reply (1)

• !Report Abuse
View all 1 replies
John Rayhall: ILMN is down 36% pre-market seems a little overdone no?
10/7/11
• !Report Abuse
Add a reply...

140 characters

Joshua Hayes
new instablog: Rally Attempt Begins with Two Days of Gains. Medical stocks are our leaders. VRUS ELN JAZZ STAA ALXN BIIB RGEN MAKO OSUR BMY
10/5/11
Reply (1)

• !Report Abuse
View all 1 replies
cowpieTX: i manage a diagnostic imaging center for a 17b market cap company. the cuts are real and they are deep. tread carefully.
10/5/11
• !Report Abuse
Add a reply...

140 characters

VRUS Pharmasset, Inc.

VRUS

Pharmasset, Inc.